Latest News

On June 16, 2026, the U.S. Food and Drug Administration (FDA) approved Rextovy (naloxone hydrochloride 4 mg) nasal spray for over-the-counter (OTC) use in the…

PEGUS Research is very excited to announce the addition of Katie Montenegro to our Executive Leadership Team as Associate Vice President of Project Management. Katie…

On July 13, 2023, the FDA approved the first nonprescription progestin-only oral contraceptive pill in the US: https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive. PEGUS was pleased to have one of…

On March 29, 2023, the FDA approved the first OTC naloxone nasal spray in the US: https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray. PEGUS was pleased to have one of our…

PEGUS is pleased to announce the following additions to our team: Lisa Fairfax, MBA: Lisa is our new Business Operations Manager, with responsibility for key business…

Key staff from PEGUS are pleased to participate in two upcoming public FDA advisory committee meetings for potential 1st in class OTC switch candidates we…

On July 11, a prominent PEGUS Research sponsor submitted its application to the FDA for a first-ever over-the-counter (OTC) oral contraceptive in the US. PEGUS…

On May 26, PEGUS Research CEO Clark Richardson announced features of the company’s enhanced work-from-home model. Since the pandemic, PEGUS leadership has enthusiastically embraced the…